Haleon PLC Sponsored ADR (NYSE:HLN) Receives Average Recommendation of “Moderate Buy” from Analysts

Posted by on Jul 22nd, 2026

Shares of Haleon PLC Sponsored ADR (NYSE:HLN – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and two have given a strong buy rating to the company.

A number of equities research analysts have recently issued reports on HLN shares. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Finally, Rothschild & Co Redburn downgraded shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th.

Get Our Latest Stock Report on HLN

Hedge Funds Weigh In On Haleon

Institutional investors have recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new stake in shares of Haleon during the first quarter valued at about $29,000. Parkside Financial Bank & Trust lifted its stake in shares of Haleon by 101.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after acquiring an additional 1,433 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC lifted its stake in shares of Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after acquiring an additional 2,404 shares in the last quarter. Stance Capital LLC purchased a new position in Haleon in the third quarter valued at about $34,000. Finally, Geneos Wealth Management Inc. boosted its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Down 1.0%

Shares of HLN opened at $9.94 on Wednesday. The stock’s 50-day moving average is $9.31 and its two-hundred day moving average is $9.86. The stock has a market cap of $43.76 billion, a PE ratio of 25.47, a P/E/G ratio of 2.32 and a beta of 0.13. Haleon has a 12 month low of $8.65 and a 12 month high of $11.28. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71.

Haleon Company Profile

(Get Free Report)

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.

Featured Articles

Analyst Recommendations for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.